Literature DB >> 15626017

Tumor angiogenesis and outcome in osteosarcoma.

Danko Mikulić1, Ivana Ilić, Mladen Cepulić, Dubravko Orlić, Jasminka Stepan Giljević, Ivan Fattorini, Sven Seiwerth.   

Abstract

Intratumoral angiogenesis quantified by microvessel density (MVD) has been shown to be a strong prognostic indicator in a number of malignant tumors. Its association with prognosis in bone sarcomas has been subject to less extensive research. The aim of this study was to investigate prognostic significance of angiogenesis in osteosarcoma. Thirty-nine patients with osteosarcoma were included in a retrospective immunohistochemical study. Sections from diagnostic biopsies were immunostained using anti-von Willebrand factor antibody and microvessels were counted at 400 x magnification on 3 microscopic fields per patient. MVD was correlated with overall and disease-free survival by Kaplan-Meier and log-rank analysis. Correlation between clinicopathological variables and the degree of angiogenesis was tested using a chi 2 test. Significant statistical difference was found regarding overall survival and disease-free survival between patients with high (> 32.3 vessels/field) and low (< or = 32.3 vessels/field) microvessel counts (log-rank test p = .0196 and p = .0147, respectively). The rate of metastasis was significantly higher in patients with high microvessel counts (p = .042). These findings strongly suggest that angiogenesis quantified by microvessel density is predictive of metastasis and poor prognosis in osteosarcoma.

Entities:  

Mesh:

Year:  2004        PMID: 15626017     DOI: 10.1080/08880010490501015

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  21 in total

1.  Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1.

Authors:  Wei Qu; Yufei Wang; Qining Wu; Jijun Liu; Dingjun Hao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.

Authors:  Shishir Rastogi; Ramakant Kumar; Sukesh Rao Sankineani; Kanniraj Marimuthu; Laxman Rijal; Shyam Prakash; Divesh Jalan; Shah Alam Khan; Mehar C Sharma
Journal:  Int Orthop       Date:  2012-09-27       Impact factor: 3.075

3.  The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model.

Authors:  Francisco Giner; José Antonio López-Guerrero; Isidro Machado; Zaida García-Casado; Amando Peydró-Olaya; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2015-06-09       Impact factor: 4.064

4.  Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model.

Authors:  Hairong Xu; Xiaohui Niu; Qing Zhang; Lin Hao; Yi Ding; Weifeng Liu; Lu Yao
Journal:  Oncol Lett       Date:  2011-07-04       Impact factor: 2.967

5.  Possible prognostic role of IL-17R in osteosarcoma.

Authors:  Maria Cristina Honorati; Luca Cattini; Andrea Facchini
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-10       Impact factor: 4.553

6.  The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7.

Authors:  Tanmayi P Mankame; Mark W Lingen
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

7.  Diversity of angiogenesis among malignant bone tumors.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Koji Arihiro; Mitsuo Ochi
Journal:  Mol Clin Oncol       Date:  2012-08-10

8.  VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway.

Authors:  Jian Zhao; Zi-Ru Zhang; Na Zhao; Bao-An Ma; Qing-Yu Fan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 9.  Tissue-engineered 3D models for elucidating primary and metastatic bone cancer progression.

Authors:  Eva C González Díaz; Sauradeep Sinha; Raffi S Avedian; Fan Yang
Journal:  Acta Biomater       Date:  2019-08-13       Impact factor: 8.947

10.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.